Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 53 clinical trials
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.

BRCA2
cytokines
cancer
colon cancer
BRCA1
  • 14 views
  • 24 Apr, 2022
  • 1 location
Adjuvant Low Dose Aspirin in Colorectal Cancer (ALASCCA)

ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.

rectal carcinoma
aspirin
  • 29 views
  • 03 May, 2022
  • 32 locations
Sirolimus for Cowden Syndrome With Colon Polyposis

Colon polyposis (the presence of multiple colon polyps) is very common with Cowden syndrome, as over 60% of patients have 50 or more polyps. In a previous clinical trial, some participants had reduction in the number of colon polyps with the use of the medication sirolimus for a very short …

  • 0 views
  • 30 Nov, 2021
  • 1 location
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma. Carboplatin will be added to sensitize the tumor to PARP inhibition, and low dose radiation therapy will be applied to increase talazoparib …

  • 0 views
  • 25 Aug, 2021
  • 1 location
Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors With PIK3CA Mutations

This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib when combined with an ISD with a goal of reducing side effects and enhancing anticancer activity.

  • 0 views
  • 24 Apr, 2022
  • 1 location
AZD8186 and Paclitaxel in Advanced Gastric Cancer

. AZD8186 has shown significant anti-tumor activity in PTEN-deficient preclinical models, including prostate, triple negative breast cancer, squamous lung and germinal center diffuse large B-cell lymphoma

growth factor
breast cancer
liver metastasis
recurrent gastric cancer
human chorionic gonadotropin
  • 8 views
  • 11 Feb, 2022
  • 1 location
Study of Copanlisib and Ketogenic Diet

: (a) relapsed or refractory (R/R) follicular lymphoma (FL), (b) R/R endometrial cancer (EC) with a documented activating mutation in PIK3CA or loss of phosphatase and tensin homolog (PTEN).

PIK3CA
cancer
measurable disease
ejection fraction
follicular lymphoma
  • 0 views
  • 15 Dec, 2021
  • 1 location
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

that have spread to other places in the body (advanced) and have changes in PIK3CA and PTEN genes. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

nivolumab
solid tumour
liver metastasis
glycosylated hemoglobin
metastasis
  • 0 views
  • 23 Apr, 2022
  • 5 locations
Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

efficacy of paclitaxel and AZD8186 combination therapy as a second-line therapy in patients with advanced gastric cancer with PTEN aberrations. This study is divided into Phase IB and Phase II.

immunostimulants
neutrophil count
fluoropyrimidine
measurable disease
adjuvant chemotherapy
  • 0 views
  • 01 Sep, 2021
  • 2 locations
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

treating patients with HER2 positive stage IV breast cancer with PIK3CA or PTEN mutation. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab

trastuzumab
breast cancer
liver metastasis
metastasis
endocrine therapy
  • 1 views
  • 23 May, 2022
  • 2 locations